Does Medicare Cover Zepbound?

Key Takeaways: Medicare and Zepbound Coverage in 2026 💡

Does Medicare cover Zepbound for weight loss? No. Federal law still prohibits Medicare Part D from covering any drug prescribed solely for weight loss, including Zepbound.

Is there any pathway to get Zepbound through Medicare? Yes. Medicare Part D may cover Zepbound when prescribed specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

What about the $50/month deal? Starting as early as July 2026, a new Medicare GLP-1 payment demonstration will cap beneficiary costs at $50 per month for eligible enrollees through a program negotiated between the government and Eli Lilly.

Does Medicare cover Wegovy? Yes, but only when prescribed for cardiovascular risk reduction in adults with established heart disease who are overweight or obese. Not for weight loss alone.

Does Medicare cover Mounjaro? Medicare Part D may cover Mounjaro (tirzepatide) when prescribed for type 2 diabetes management, since that is its FDA-approved indication. It is not covered for weight loss.

What is the BALANCE Model? A new CMS voluntary program launching in Medicare Part D in January 2027 that would allow participating plans to cover GLP-1 drugs for weight management at negotiated prices.

How much does Zepbound cost on Medicare right now? If covered for OSA, expect to pay $250 to $400+ per month until you reach the $2,100 annual Part D out-of-pocket cap for 2026. After that, you pay $0 for the rest of the year.

Do states matter for Medicare coverage? Medicare is a federal program, so the Part D exclusion on weight-loss drugs applies nationwide. However, state Medicaid programs vary dramatically, and the BALANCE Model’s Medicaid expansion will depend on which states opt in.

Can I use the Zepbound Savings Card with Medicare? No. Eli Lilly’s $25/month savings card is only available to people with commercial insurance. Medicare, Medicaid, and other government-sponsored insurance beneficiaries are excluded.

What is TrumpRx? A new direct-to-consumer website where anyone, including Medicare beneficiaries, can purchase GLP-1 medications at discounted manufacturer prices, though you’d be paying out of pocket.

---

🏥 Medicare Cannot Cover Zepbound for Weight Loss — and Here’s the Law Behind It

This is the single most important thing to understand, and most articles bury it. The Medicare Modernization Act of 2003 specifically prohibits Medicare from covering weight loss drugs. That statute has not been repealed or amended. It means that no matter how effective Zepbound is for shedding pounds, GLP-1 use for weight-loss-only purposes is excluded from Medicare Part D coverage, meaning plans are not allowed to cover them for that purpose alone.

This isn’t a loophole that plans are choosing not to fill. It’s a legal barrier built into the program.

Scenario	Covered by Medicare?	Why?
💊 Zepbound for weight loss only	❌ No	Federal law excludes weight-loss drugs from Part D
😴 Zepbound for obstructive sleep apnea	✅ Possible	FDA-approved indication beyond weight loss
🫀 Wegovy for cardiovascular risk	✅ Possible	FDA-approved for heart disease risk reduction
🩸 Mounjaro/Ozempic for type 2 diabetes	✅ Possible	FDA-approved for blood sugar management
⚖️ Any GLP-1 for obesity alone	❌ No	Statutory exclusion still in effect

💡 Pro Tip: The critical distinction is the diagnosis code your doctor writes on the prescription. The same molecule (tirzepatide) is sold as Zepbound for weight loss and sleep apnea, and as Mounjaro for type 2 diabetes. Coverage hinges entirely on the FDA-approved indication and your doctor’s documentation.

---

😴 The Sleep Apnea Pathway: How Seniors Are Actually Getting Zepbound Through Medicare Right Now

Here’s the workaround that’s already working for thousands of Medicare beneficiaries. The FDA approved Zepbound for adults with moderate-to-severe obstructive sleep apnea who are also obese in December 2024. Because sleep apnea is a covered medical condition (not a “weight loss” indication), this opened a legitimate door.

To qualify, you need all of the following:

A confirmed diagnosis of moderate-to-severe obstructive sleep apnea, typically documented through a sleep study. A body mass index (BMI) of 27 or higher. Participation in a reduced-calorie diet and increased physical activity program. Enrollment in a Medicare Part D plan (standalone or bundled through Medicare Advantage). Prior authorization from your doctor, which most plans require.

Medicare only covers Zepbound for obstructive sleep apnea and not for central sleep apnea (CSA). And it does not cover Zepbound for diabetes or cardiovascular disease, since those are not FDA-approved indications for this particular brand.

Step	What You Need	Who Handles It
1️⃣ Diagnosis	Sleep study confirming moderate-to-severe OSA	Your doctor or sleep specialist
2️⃣ BMI check	BMI of 27+ documented in medical records	Your primary care provider
3️⃣ Prior authorization	PA form submitted to your Part D plan	Your prescribing physician
4️⃣ Plan verification	Confirm Zepbound is on your plan’s formulary	You (call 1-800-MEDICARE or check online)
5️⃣ Fill prescription	Pick up at pharmacy once approved	Your pharmacy

💡 Pro Tip: Not all Part D plans have added Zepbound to their formulary for the OSA indication. Use Medicare’s online plan comparison tool at Medicare.gov to check your specific plan before assuming coverage.

---

💰 How Much You’ll Actually Pay for Zepbound on Medicare in 2026

Let’s talk real numbers. The 2026 Part D out-of-pocket cap is $2,100 (up from $2,000 in 2025), and the maximum deductible is $615. Zepbound is typically placed on Tier 4 or 5 (specialty tier), which means you’ll face percentage-based coinsurance rather than flat copays.

Here’s how the math breaks down if your plan covers Zepbound for OSA:

Cost Phase	What You Pay	Details
💵 Deductible phase	100% of drug cost	Until you spend $615
📊 Initial coverage phase	~25-33% coinsurance	Typically $250-$400+ per month
🎉 After hitting $2,100 cap	$0	Plan covers 100% for rest of year
⏳ Yearly reset	Starts over January 1	New deductible and cap each year

The practical reality is that most beneficiaries on Zepbound will hit that $2,100 annual cap within the first few months of the year, since Zepbound’s list price exceeds $1,000 per month. After that, you pay nothing for the rest of the calendar year.

The $50/month game-changer coming in 2026: Eli Lilly announced an agreement with the U.S. government that, starting as early as April 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound through a multi-dose pen format. CMS also plans to implement a new Medicare GLP-1 payment demonstration beginning July 2026 where eligible Medicare Part D enrollees will pay $50 for a month of GLP-1 medications.

💡 Pro Tip: If you qualify for Medicare’s Extra Help (Low-Income Subsidy) program, copays drop to around $4.90 for generics and $12.15 for brand-name drugs, which could dramatically reduce your Zepbound costs even before the new pricing kicks in.

---

🫀 Does Medicare Cover Wegovy? Yes, but Only Through the Heart Disease Door

Wegovy (semaglutide) has a unique advantage over Zepbound when it comes to Medicare coverage. The FDA officially approved Wegovy for reducing the risk of heart attack and stroke in people with cardiovascular disease, so it is now covered by Medicare under certain conditions.

Here’s the catch: Medicare Part D may only cover Wegovy when it is prescribed for cardiovascular risk reduction in patients with established heart disease who are overweight or obese. You must have documented cardiovascular disease, which includes a history of heart attack, stroke, or peripheral arterial disease. No heart disease diagnosis means no coverage, period.

Based on KFF analysis of Medicare data, an estimated 3.6 million Medicare beneficiaries had established cardiovascular disease and obesity or overweight, making them potentially eligible.

GLP-1 Drug	Medicare Coverage Pathway	Required Diagnosis
💊 Zepbound (tirzepatide)	Sleep apnea pathway	Moderate-to-severe OSA + obesity
💊 Wegovy (semaglutide)	Cardiovascular pathway	Established heart disease + overweight/obesity
💊 Mounjaro (tirzepatide)	Diabetes pathway	Type 2 diabetes
💊 Ozempic (semaglutide)	Diabetes pathway	Type 2 diabetes
💊 Rybelsus (semaglutide)	Diabetes pathway	Type 2 diabetes

💡 Pro Tip: Individual Part D plans still control their formularies, so plans may choose to include Wegovy, restrict it with prior authorization, or place it on a higher cost-sharing tier. Always verify with your specific plan during open enrollment.

---

🗺️ State-by-State Medicaid Coverage: Where GLP-1s Stand Right Now

While Medicare is a federal program with uniform rules, Medicaid coverage for GLP-1 obesity drugs varies wildly by state. This matters because many seniors are dual-eligible (qualifying for both Medicare and Medicaid), and Medicaid can help cover costs that Medicare doesn’t.

As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment. And the landscape is shifting in the wrong direction for some states. Four states — California, New Hampshire, Pennsylvania, and South Carolina — eliminated coverage of GLP-1s for obesity treatment since October 2025, driven by budget constraints.

Coverage Status	States	Key Details
✅ Currently covering GLP-1s for obesity	Massachusetts, Minnesota, Mississippi, Wisconsin, Michigan*, North Carolina**, Virginia, Kansas, Delaware, Rhode Island and others	*Michigan restricted to morbid obesity only; **NC reinstated Dec 2025
❌ Recently ended obesity coverage	California, New Hampshire, Pennsylvania (adults 21+), South Carolina	Effective January 1, 2026
⚠️ Considering restrictions	Connecticut, Rhode Island, Wisconsin	Budget pressures mounting
🔄 CVD indication only (not obesity)	Kansas, Vermont	Cover GLP-1s for heart conditions, not weight loss
📋 All states cover for type 2 diabetes	All 50 states + DC	Required under Medicaid Drug Rebate Program

In January 2025, North Dakota became the first state to mandate insurance coverage for GLP-1 and GIP medications by amending its Essential Health Benefit benchmark, setting a precedent that other states are watching closely.

💡 Pro Tip: Even if your state Medicaid program doesn’t cover GLP-1s for obesity, it must cover them for FDA-approved conditions like type 2 diabetes and (since the recent FDA approvals) for cardiovascular risk reduction and obstructive sleep apnea. Talk to your doctor about all your diagnoses.

---

🔮 The BALANCE Model and July 2026 Bridge Program: What’s Actually Coming

Two major federal initiatives are set to reshape Medicare and Medicaid GLP-1 access in 2026 and 2027:

The Medicare GLP-1 Payment Demonstration (July 2026): CMS plans to implement a new GLP-1 payment demonstration beginning July 2026 that will serve as a short-term bridge. Under this demonstration, eligible Medicare Part D enrollees will pay $50 for a month of GLP-1 medications. This program operates outside the normal Part D benefit structure, meaning your plan won’t carry the financial risk.

The BALANCE Model (January 2027 for Medicare Part D): CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors. State Medicaid agencies can join the model beginning in May 2026, and Part D plans in January 2027. The model will run through December 2031.

There are important caveats. Participation in the BALANCE Model is voluntary, so GLP-1 drug manufacturers, state Medicaid programs, and Medicare insurance plans may all choose whether to participate. No one is required to join. Your access depends entirely on which entities opt in.

Program	Launches	Cost to You	Who’s Eligible
🌉 Medicare GLP-1 Demonstration	July 2026	$50/month	Medicare Part D enrollees meeting negotiated criteria
⚖️ BALANCE Model (Medicaid)	May 2026	Varies by state	Medicaid enrollees in participating states
⚖️ BALANCE Model (Medicare Part D)	January 2027	$50/month expected	Part D enrollees in participating plans
🏷️ TrumpRx website	Early-mid 2026	~$245-350/month	Anyone, including Medicare beneficiaries (cash pay)

💡 Pro Tip: Consumers who are overweight and have prediabetes, or who have had a stroke or other cardiovascular disease, will be eligible, as will those who have obesity and diabetes or uncontrolled high blood pressure and severe obesity. This isn’t open to everyone on Medicare — you’ll need obesity plus a qualifying health condition.

---

🚫 What Medicare Beneficiaries Cannot Do (Common Misconceptions)

Let’s clear up the most persistent myths:

You cannot use Eli Lilly’s Zepbound Savings Card. People covered by government-sponsored insurance, including Medicare and Medicaid, are not eligible for this program. That $25/month coupon you’ve seen advertised is exclusively for commercially insured patients.

You cannot get your doctor to simply write “obesity” as the reason and expect coverage. The Medicare statutory exclusion specifically targets drugs prescribed for weight loss. Even off-label prescribing won’t override this legal prohibition.

You cannot assume your Medicare Advantage plan covers more than Original Medicare. Medicare Advantage (Part C) plans with prescription drug coverage must follow the same federal exclusion for weight loss drugs.

Myth	Reality	What to Do Instead
🚫 “My doctor can prescribe it for weight loss”	Federal law blocks Part D from covering it	Ask about sleep apnea or heart disease pathways
🚫 “The Lilly savings card will help”	Not available to Medicare/Medicaid patients	Look into Extra Help, TrumpRx, or pharmacy discounts
🚫 “Medicare Advantage plans cover more”	Same federal exclusion applies	Compare MA-PD formularies during open enrollment
🚫 “All plans cover Zepbound for sleep apnea”	Not all plans have added it to their formulary	Check your plan’s formulary at Medicare.gov

---

📋 Frequently Asked Questions

Can I get Zepbound if I’m on Medicare and have no other conditions besides obesity?

Not through Medicare, at least not until the July 2026 demonstration program launches. Right now, you’d need a qualifying diagnosis like obstructive sleep apnea or (through the upcoming BALANCE Model) obesity plus a comorbid condition. If you want Zepbound sooner, your options include paying out of pocket through TrumpRx or manufacturer programs, or asking your doctor if you might qualify for a sleep study.

Does Medicare cover Zepbound for sleep apnea in every state?

Medicare is a federal program, so the rules are the same regardless of your state. If your Medicare Part D plan includes Zepbound on its formulary for the OSA indication, and you meet the eligibility criteria, you can get coverage whether you live in Texas or Vermont. However, not every Part D plan has added Zepbound for this use, so you need to verify with your specific plan.

Is the $50/month Zepbound price guaranteed?

The agreement between Eli Lilly and the U.S. government sets this cap, but it applies to a specific multi-dose pen formulation and requires the July 2026 demonstration to launch on schedule. Implementation details are still being finalized. Until then, costs are based on your existing Part D plan structure.

What if I have both Medicare and Medicaid (dual eligible)?

Dual-eligible beneficiaries get their prescription drug coverage through Medicare Part D, not Medicaid. So the Part D rules about weight-loss exclusion still apply. However, if you qualify for Extra Help (the Low-Income Subsidy), your Part D cost-sharing will be significantly reduced for any covered medications.

Should I switch Medicare plans to get Zepbound covered?

If your current plan doesn’t cover Zepbound for OSA but another plan in your area does, switching during the Annual Enrollment Period (October 15 through December 7) or the Medicare Advantage Open Enrollment (January 1 through March 31) could be worth it. Use the Medicare Plan Finder tool to compare formularies before making any changes.

What is TrumpRx and can Medicare patients use it?

TrumpRx is a direct-to-consumer website launching in early-to-mid 2026 where consumers can purchase GLP-1 medications at manufacturer-negotiated prices. Medicare beneficiaries can use it, but you’d be paying out of pocket since it bypasses insurance entirely. Prices are expected to be significantly lower than full retail but still higher than the $50/month coming through the Medicare demonstration.

Does Medicare cover the new Wegovy pill?

The FDA approved an oral (pill) version of Wegovy in December 2025. Medicare coverage rules for the pill are the same as for the injection: it can be covered only for the cardiovascular risk reduction indication, not for weight loss alone. The pill version offers a more convenient option for patients who qualify.

Will Medicare ever fully cover GLP-1s for weight loss?

That would require Congress to change the Medicare Modernization Act of 2003. While the BALANCE Model and demonstration programs represent creative workarounds, they don’t change the underlying law. Multiple legislative proposals have been introduced over the years, but none have passed. The trend is toward broader access, but universal Medicare coverage for obesity drugs is not guaranteed.